Welcome to our dedicated page for Lunai Bioworks news (Ticker: LNAI), a resource for investors and traders seeking the latest updates and insights on Lunai Bioworks stock.
Lunai Bioworks Inc. develops AI-enabled life sciences platforms for drug discovery, precision therapeutics and chemical defense applications. Company news centers on the Augusta platform, BioSymetrics' phenotypic screening and machine-learning capabilities, and programs tied to central nervous system diseases, oncology and biodefense.
Recurring updates include intellectual property additions, patent issuances, commercial collaborations, defense-focused chemical threat assessment work, and capital transactions used to support platform expansion. Recent company developments also cover CNS delivery technologies, neurotherapeutic patent assets, patient-stratification methods, and the integration of clinical, genomic and phenotypic data into drug discovery workflows.
Lunai Bioworks (NASDAQ:LNAI) says its Augusta AI platform is now commercial after 12 months of development and is in active negotiations with pharmaceutical and drug‑discovery partners. The company highlights three revenue engines: AI drug discovery (CNS and new oncology pilot), AI biodefense programs targeting government contracts, and an allogeneic dendritic cell immunotherapy with published preclinical tumor regressions and an LOI for licensing.
The release emphasizes faster target validation via high‑throughput in vivo testing, near‑term pilots that can expand to commercial relationships, and ongoing efforts to finalize biodefense funding and a pharma royalty partnership.
Lunai Bioworks (NASDAQ: LNAI) launched an AI oncology pilot on Feb 9, 2026 to analyze randomized Phase 2 metastatic colorectal cancer trial data with a clinical-stage partner. The pilot uses Lunai's Augusta AI platform to evaluate de-identified patient-level clinical, imaging, and longitudinal outcomes focusing on overall survival and disease progression.
The goal is to define biologically meaningful patient subgroups to inform FDA trial design, optimized inclusion criteria, endpoint strategy, and statistical powering, with potential expansion to multi-study commercial programs and other tumor types if data support it.
Lunai Bioworks (NASDAQ: LNAI) launched Sentinel, a transformer-based AI safeguard that embeds inside large language and scientific foundation models to screen and block generation of novel chemical threat agents in real time. Sentinel combines Lunai's chemical foundation model trained on ~550 million public chemical structures and fine-tuned with the company's proprietary in-vivo toxicology and phenotypic datasets to detect latent toxic signatures and mechanisms, including neurotoxic and cytotoxic patterns. The product is positioned as part of a three-program biodefense strategy alongside Pathfinder and Counteract and targets AI developers, government agencies, and life-science platforms seeking integrated molecular-level biosecurity.
Lunai Bioworks (NASDAQ: LNAI) completed an NIH STTR commercial milestone creating high-resolution, multidimensional behavioral signatures of ethanol exposure and withdrawal and has launched a commercial Alcohol Use Disorder (AUD) drug-discovery program.
The program uses scalable high-throughput vertebrate screening, targets underexplored mechanisms, is supported by NIH funding, and is run in collaboration with Dr. Calum MacRae at Brigham and Women's Hospital/Harvard Medical School.
Company cites a large unmet need: ~30 million U.S. individuals affected, ~95% receiving no effective pharmacologic treatment, and a ~$250 billion annual economic cost.
Lunai Bioworks (NASDAQ: LNAI) was featured in International Business Times on Dec 17–18, 2025 for advancing AI-enabled drug discovery and active partnership discussions around multiple CNS programs, including Parkinson's, Alzheimer's and epilepsy.
The piece highlights Lunai's Augusta platform integrating longitudinal clinical data, large-scale proteomics and phenotypic analysis, use of PPMI Parkinson's data to identify patient subtypes and targets, and the company's focus on non-dilutive partnerships to extend runway and validate the platform.
Market context cited includes recent landmark AI-drug deals, an estimated $240 billion revenue-at-risk tailwind, ~$1.3 trillion capital for external innovation, ~11 million shares sold short vs a post-split float of ~23 million, and a 2025 market-cap reset from >$350M to $30M.
Lunai Bioworks (NASDAQ: LNAI) announced identification of three clinically relevant Parkinson's disease subtypes and prioritized drug targets intended to accelerate proof-of-concept programs and strategic partnerships.
Analysis integrated longitudinal clinical and proteomic data from >650 participants and ~4,500 proteomic probes (median follow-up ≥2.5 years), linking subtypes to rapid progression, cognitive decline, and functional impairment. Lunai is initiating experimental validation, preclinical model development, and biomarker qualification while evaluating co-development opportunities in a market projected to exceed $13 billion by the 2030s.
Lunai Bioworks (NASDAQ: LNAI) announced it has secured a first letter of intent (LOI) to license its next‑generation dendritic cell combination therapy (DCCT) after peer‑reviewed publication and independent expert review. In humanized mouse models of pancreatic cancer, the DCCT produced complete regression of primary and metastatic tumors with no recurrence and 80–90% tumor size reduction across two studies. Lunai also reported a successful pre‑IND meeting with the FDA and plans for formal licensing negotiations and pre‑IND activities in early 2026 toward a proposed Phase I trial for high‑need solid tumors.
Lunai Bioworks (NASDAQ: LNAI) announced that a second‑generation, clinical‑grade dendritic cell (DC) therapy produced complete regression of primary and metastatic pancreatic tumors in preclinical humanized mouse models.
The Brief Report was published in Vaccines on Nov 2, 2025 and describes an optimized, clinically compliant construct that preserves the original product's efficacy while improving promoter and manufacturing elements to support IND‑enabling studies.
The therapy triggered robust activation of cytotoxic T cells and NK cells, and the company says the data advance partnering conversations and the platform's translation toward clinical development.
Lunai Bioworks (NASDAQ:LNAI) announced early results from an AI-driven platform that identifies compounds interacting with acetylcholinesterase (AChE), the molecular target of nerve agents. The company reported its predictive model achieved 0.94 AUROC for distinguishing active AChE inhibitors from inactive compounds and flagged previously unidentified candidate neurotoxic compounds for follow-up. Lunai plans to combine the AI predictions with behavioral zebrafish profiling to observe real-time physiological effects and prioritize countermeasures. The company also embedded the model in a partner dashboard to enable collaborative chemical-structure screening for potential neurotoxicity.
Lunai Bioworks (NASDAQ:LNAI) subsidiary BioSymetrics and academic partners published a Nature Communications study (Oct 16, 2025) reporting prognostic serum protein biomarkers for Duchenne muscular dystrophy (DMD).
The multi‑institutional analysis used the SomaScan proteomics platform on >700 longitudinal serum samples from European and U.S. cohorts and identified proteins including RGMA, ART3, and ANTXR2 that associate with motor performance and predict outcomes such as loss of ambulation and upper‑limb decline.
Authors say these minimally invasive biomarkers could refine clinical trial enrollment, improve stratification, and support more personalized patient management, while results were cross‑cohort validated and controlled for age and corticosteroid use.